Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers01:17

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers

Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline moieties. Phenoxybenzamine, with a haloalkylamine...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cardiotoxicity of Breast Cancer Chemotherapy.

Cardiology in review·2023
Same author

Left Atrial Appendage Closure: What Do We Know?

Cardiology in review·2023
Same author

Impact of Balloon Pulmonary Angioplasty on Right Ventricular Function in Patients With Chronic Thromboembolic Pulmonary Hypertension.

Cardiology in review·2023
Same author

Antiphospholipid Syndrome: Thrombotic and Vascular Complications.

Cardiology in review·2023
Same author

Baxdrostat: An Aldosterone Synthase Inhibitor for the Treatment of Systemic Hypertension.

Cardiology in review·2023
Same author

New Therapy Update Aprocitentan: An Endothelin Receptor Antagonist for the Treatment of Drug-Resistant Systemic Hypertension.

Cardiology in review·2023

Related Experiment Video

Updated: May 29, 2026

Measuring the Rate of Lipolysis in Ex Vivo Murine Adipose Tissue and Primary Preadipocytes Differentiated In Vitro
09:41

Measuring the Rate of Lipolysis in Ex Vivo Murine Adipose Tissue and Primary Preadipocytes Differentiated In Vitro

Published on: March 17, 2023

β-Adrenergic blockers.

William H Frishman1, Elijah Saunders

  • 1Department of Medicine, New York Medical College/Westchester Medical Center, Valhalla, NY, USA. william_frishman@nymc.edu

Journal of Clinical Hypertension (Greenwich, Conn.)
|September 8, 2011
PubMed
Summary
This summary is machine-generated.

Beta-blockers are effective for hypertension, heart conditions, and arrhythmias. Their varied properties require careful selection for optimal patient outcomes and safety.

More Related Videos

Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker
08:32

Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker

Published on: December 18, 2014

Related Experiment Videos

Last Updated: May 29, 2026

Measuring the Rate of Lipolysis in Ex Vivo Murine Adipose Tissue and Primary Preadipocytes Differentiated In Vitro
09:41

Measuring the Rate of Lipolysis in Ex Vivo Murine Adipose Tissue and Primary Preadipocytes Differentiated In Vitro

Published on: March 17, 2023

Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker
08:32

Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker

Published on: December 18, 2014

Area of Science:

  • Pharmacology
  • Cardiology
  • Clinical Medicine

Background:

  • Beta-blockers are widely used for cardiovascular conditions.
  • Their diverse pharmacologic profiles necessitate careful consideration for clinical application.
  • Recent evidence suggests a more nuanced role in perioperative settings.

Purpose of the Study:

  • To outline appropriate uses of beta-blockers.
  • To highlight the heterogeneity of beta-blocker pharmacologic effects.
  • To clarify evidence-based indications for beta-blocker therapy.

Main Methods:

  • Review of key points and practical recommendations regarding beta-blocker use.
  • Analysis of pharmacologic properties influencing drug selection.
  • Evaluation of current evidence for specific clinical scenarios.

Main Results:

  • Beta-blockers are indicated for hypertension, ischemic heart disease, heart failure, certain arrhythmias, and hyperkinetic circulation.
  • Labetalol is suitable for hypertensive emergencies.
  • Heterogeneity in properties like selectivity, sympathomimetic activity, and elimination routes impacts clinical choice.
  • Perioperative use may not benefit all patients and can cause harm; evidence supports use in specific vascular surgery and pre-existing cardiovascular conditions.

Conclusions:

  • Beta-blockers are valuable for hypertension and various cardiovascular diseases.
  • Understanding drug-specific properties is crucial for effective and safe prescribing.
  • Evidence supports targeted use in specific patient populations, particularly those with known cardiovascular conditions or undergoing vascular surgery.